Literature DB >> 30138540

Cancer of the gastroesophageal junction: a diagnosis, classification, and management review.

Mickael Chevallay1, Elfriede Bollschweiler2, Servarayan M Chandramohan3, Thomas Schmidt4, Oliver Koch5, Giovanni Demanzoni6, Stefan Mönig1, William Allum7.   

Abstract

Management of gastroesophageal junction (GEJ) adenocarcinoma is a controversial topic. The rising incidence of this cancer requires a clear consensus to ensure proper management. Application of oncological principles for tumors of the esophagus or stomach is not possible because of comparative differences in the biology of GEJ adenocarcinoma, leading to different therapeutic options. Staging work-up with endoscopy, endosonography, and PET is essential to inform the choice of neoadjuvant treatment and surgical approach to GEJ adenocarcinoma. Surgery remains the only curative treatment and should be undertaken in specialized centers.
© 2018 New York Academy of Sciences.

Entities:  

Keywords:  FLOT; esophagectomy; minimally invasive

Mesh:

Year:  2018        PMID: 30138540     DOI: 10.1111/nyas.13954

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.

Authors:  Vittoria Matilde Piva; Maria Caterina De Grandis; Michele Valmasoni; Sara Lonardi; Irene Sole Zuin; Valentina Angerilli; Floriana Nappo; Rita Alfieri; Selma Ahcene Djaballah; Sabina Murgioni; Francesca Bergamo; Matteo Fassan
Journal:  Updates Surg       Date:  2022-10-22

2.  Scaphoid metastasis as the first sign of occult gastroesophageal junction cancer: A case report.

Authors:  Yu-Jie Zhang; Yan-Yan Wang; Qi Yang; Jian-Bing Li
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

3.  Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.

Authors:  Jian Chen; Yu-Jian Xia; Tian-Yu Liu; Yuan-Hui Lai; Ji-Shang Yu; Tian-Hao Zhang; Shiyin Ooi; Yu-Long He
Journal:  BMC Cancer       Date:  2021-05-10       Impact factor: 4.430

4.  Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis.

Authors:  Ji Cheng; Ming Cai; Xiaoming Shuai; Jinbo Gao; Guobin Wang; Kaixiong Tao
Journal:  Ther Adv Med Oncol       Date:  2019-04-02       Impact factor: 8.168

5.  Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis.

Authors:  Oliver O Koch; Michael Weitzendorfer; Martin Varga; Andreas Tschoner; Richard Partl; Alexander Perathoner; Philipp Gehwolf; Karin S Kapp; Reinhold Függer; Dietmar Öfner; Klaus Emmanuel
Journal:  World J Surg Oncol       Date:  2019-08-19       Impact factor: 2.754

Review 6.  Narrative review of the role of gastroenterologist in the diagnosis, treatment and palliation in gastric and gastroesophageal cancer.

Authors:  Liege I Diaz; Shruti Mony; Jason Klapman
Journal:  Ann Transl Med       Date:  2020-09

Review 7.  The Impact of Whole Grain Intake on Gastrointestinal Tumors: A Focus on Colorectal, Gastric, and Esophageal Cancers.

Authors:  Valentina Tullio; Valeria Gasperi; Maria Valeria Catani; Isabella Savini
Journal:  Nutrients       Date:  2020-12-29       Impact factor: 5.717

8.  Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.

Authors:  Ling-Yu Chu; Jian-Yuan Zhou; Yi-Xuan Zhao; Yan-Ting Ou; Tian Yang; Yu-Hui Peng; Wang-Kai Fang; Yi-Wei Xu; Jian-Jun Xie
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

9.  Effect of multidisciplinary team care on survival of oesophageal cancer patients: a retrospective nationwide cohort study.

Authors:  Pei-Tseng Kung; Wen-Chen Tsai; Yuan-Chun Huang; Shang-Yun Ho; Yeu-Sheng Tyan; Li-Ting Chiu
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  NCAPG Induces Cell Proliferation in Cardia Adenocarcinoma via PI3K/AKT Signaling Pathway.

Authors:  Xinxin Zhang; Hui Wang; Yajuan Han; Mengqi Zhu; Zaozhi Song; Dankai Zhan; Jianguang Jia
Journal:  Onco Targets Ther       Date:  2020-11-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.